<a href="https://www.fiercebiotech.com/biotech/first-public-cnpv-hearing-support-industry-and-deep-concern-experts" hreflang="en">At first public hearing for FDA’s CNPV program, industry support meets ‘deep concern’ from experts</a>
At the FDA's first public hearing for the Commissioner’s National Priority Voucher (CNPV) program, industry representatives expressed support, while health experts raised concerns about transparency and potential political influence in the voucher selection process. Patient advocates also called for greater inclusion of patient voices and equitable access to promising treatments through the program.
The FDA's Commissioner’s National Priority Voucher (CNPV) program, while supported by industry giants like Johnson & Johnson and Merck for its ability to streamline drug approval processes, faces significant criticism from experts over issues of politicization, transparency, and resource strains. For a professional in healthtech and biotech, this highlights the importance of monitoring regulatory frameworks and their implications on drug approval timelines and processes, as they can significantly affect the operational strategies of biotech companies and influence investor confidence in drug development ventures.